TGFB1 and osteogenesis imperfecta: Another drug, Fresolimumab, a GC1008 antibody that inhibits TGF-β, previously used to treat cancer patients [42], is currently in clinical trials to verify its safety and efficacy in the treatment of OI in adult patients [39,43].